Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Journey Medical Corp (DERM) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 41 employees
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Total Value
-$367,846.02
Total Shares
-71,921
Average Trade Value
-$91,961.51
Most Active Insider
Maraoui Claude
Total Activity: $360,762
Largest Single Transaction
$145,661
by Maraoui Claude on Mar 4, 2025
30-Day Activity
2 Transactions
Volume: 47,048 shares
Value: $238,755
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
President CEO
Director, Officer
|
Mar 5, 2025 | 18,147 | $93,094 | 2,092,874 (-0.9%) | Sale | |
President CEO
Director, Officer
|
Mar 4, 2025 | 28,901 | $145,661 | 2,111,021 (-1.4%) | Sale | |
President CEO
Director, Officer
|
Mar 3, 2025 | 23,508 | $122,007 | 2,139,922 (-1.1%) | Sale | |
CFO
Officer
|
Feb 21, 2025 | 1,365 | $7,084 | 45,966 (-3.0%) | Sale |